Log In
BCIQ
Print this Print this
 

ARN-810, GDC-0810, RG6046

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionOral selective estrogen receptor degrader (SERD)
Molecular Target Estrogen receptor 1 (ESR1)
Mechanism of ActionEstrogen receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat locally advanced or metastatic estrogen receptor-positive breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,725.0M

$725.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/27/2014

$1,725.0M

$725.0M

$1,000.0M

09/02/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today